2017 – Biobran https://biobran.org Sun, 23 Aug 2026 13:58:17 +0000 en-US hourly 1 https://wordpress.org/?v=7.1 https://biobran.org/wp-content/uploads/2026/08/cropped-FaviBB-1-32x32.webp 2017 – Biobran https://biobran.org 32 32 Urgent Necessity for Standardized and Evidence Based Plant Immunomodulators (Such As Rice Bran Arabinoxylan Concentrate/MGN-3) for the Tumor Research https://biobran.org/urgent-necessity-for-standardized-and-evidence-based-plant-immunomodulators-such-as-rice-bran-arabinoxylan-concentrate-mgn-3-for-the-tumor-research/ Wed, 16 Aug 2017 19:26:00 +0000 https://biobran.org/?p=733 Biological targeting therapies can inhibit the cascade of cell proliferation and enhance the sensitivity of malignant tumor cells against natural immune effector cells. Clinical observations suggest that their combination with evidence based and standardized plant immunomodulators (such as arabinoxylan concentrate using Biobran/MGN-3) can induce astonishing results. Since the escape of tumor cells from T lymphocytes is well known, growing interest is focusing on the Pathogenic Associated Molecular Pattern (PAMP) molecules which are able to stimulate the so called type-1 natural antitumor mechanisms in a MHC unrestricted manner. However, PAMP molecules exist only in the nature (bacteria and plants). The chemistry is not able to produce them. Bacteria are toxic. Therefore growing interest developed for the PAMP like molecules in the plants. Unfortunately, in terms of PAMP like molecules standardized plant immunomodulators (such as arabinoxylan concentrate in Biobran/MGN-3) are registered world over as food supplement and therefore their further clinical research in various oncological centers is inhibited.

]]> Can a standardized plant immunomodulator (rice bran arabinoxylan concentrate/MGN-3) increase the effects of MEK and BRAF inhibitors with clinical benefit? Case report of a patient with carcinoma in biliary duct https://biobran.org/can-a-standardized-plant-immunomodulator-rice-bran-arabinoxylan-concentrate-mgn-3-increase-the-effects-of-mek-and-braf-inhibitors-with-clinical-benefit-case-report-of-a-patient-with-carcinoma-in-bi/ Wed, 16 Aug 2017 19:22:00 +0000 https://biobran.org/?p=731 Background: Targeting hyperactive mitogen-activated protein kinase (MAPK) signaling cascade has proven to be an effective treatment for a variety of different cancers. Using an important member of this cascade, namely MEK (mitogen activated extracellular signal regulation kinase) inhibitors, the clinical responses are often transient and complete remission is rarely observed. Outgrowth of resistant clones within progressed tumors appears to be inevitable. Recent immunological and clinical observations suggest that in background of this resistance the tumor-.induced disturbance of immunoregulation at least in part may play a role. Namely, it was shown that growth factor receptor signaling pathway inhibitors can increase the immune sensitivity of tumor cells, but they can’t activate the down regulated immune effectors. Consequently, the combination of MAPK cascade signaling pathway inhibitors and the immune effectors activating immunomodulators may be a promising new strategy.

Material and methods: In a now 59 years old patient with inoperable (BRAF-mutant) low differentiated adenocarcinoma of bilary ducts after 30GY radiotherapy and two cycles (Gemcitabin+ Cisplatin) chemotherapy a rapid progression of lung, liver and brain metastases were by CT and MR established. Thereafter, a teatment with BRAF+MEK inhibitors (2×150 mg dabrafenib and 1 x 2 mg trametinib) was started. These inhibitors were combined with daily 45 mg/kg rice bran arabinoxylan concentrate (using Biobran/MGN-3) which was shown to be a pathogenic associated molecular pattern (PAMP)-like molecule and can stimulate the type-1 innate immune cells against tumor cells. Results: After the chemotherapy and prior to the start of second line treatment, the patient had a nearly terminal state of her rapidly progressive disease. Eight months after the combination of MEK / BRAF inhibitor and immunomodulator therapy nearly complete remissions of all metastases was established in CT and MR.

Conclusion: This case report may support a hypothesis that MEK / BRAF inhibitors and type-1 immune cells activating immunomodulators together may synergistic inhibit the tumor growth. Further clinical investigations are necessary to clarify this question.

]]> Biobran/MGN-3, an arabinoxylan rice bran, enhances NK cell activity in geriatric subjects: A randomized, double-blind, placebo-controlled clinical trial https://biobran.org/biobran-mgn-3-an-arabinoxylan-rice-bran-enhances-nk-cell-activity-in-geriatric-subjects-a-randomized-double-blind-placebo-controlled-clinical-trial/ https://biobran.org/biobran-mgn-3-an-arabinoxylan-rice-bran-enhances-nk-cell-activity-in-geriatric-subjects-a-randomized-double-blind-placebo-controlled-clinical-trial/#respond Wed, 16 Aug 2017 19:16:00 +0000 https://biobran.org/?p=729 Abstract. Aging is associated with a decline in natural killer (NK) and natural killer T (NKT) cell function that may contribute to increased susceptibility to malignancy and infection. A preliminary investigation was conducted examining the hypothesis that arabinoxylan rice bran (Biobran/MGN-3), a denatured hemicellulose with known immunomodulatory activity, could counteract this decline in NK/NKT cell activity in geriatrics. A total of 12 healthy geriatric subjects of both sexes and over 56 years old, participated in a randomized, double-blind, placebo-controlled clinical trial. A total of six subjects served as control and six subjects ingested Biobran/MGN-3 (500 mg/day) for 30 days. The effect of Biobran/MGN-3 supplementation on NK/NKT cell activity was assessed using the degranulation assay. All study subjects were monitored for the development of any inadvertent side effects. In addition, the pharmacological effects of Biobran/MGN-3 on blood cell components and liver and kidney functions were also assessed. Results demonstrated that Biobran/MGN-3 had no effect on the total percentage of NK cells, however it enhanced the cytotoxic activity of induced NK cell expression of cluster of differentiation 107a, when compared with baseline values and with the placebo group (P<0.05). Furthermore, there were no side effects observed, indicating that Biobran/MGN-3 supplementation was safe at the utilized dosage and for the duration of administration. Various additional beneficial effects were observed, including improved mean corpuscular volume and reduced hepatic aspartate aminotransferase enzyme levels, which suggested improved liver function. It was concluded that Biobran/MGN-3 induces a significant increase in NK activity which may increase resistance to viral infections and cancers in the geriatric population. However, additional clinical trials should be conducted in the future to verify these findings.

]]> https://biobran.org/biobran-mgn-3-an-arabinoxylan-rice-bran-enhances-nk-cell-activity-in-geriatric-subjects-a-randomized-double-blind-placebo-controlled-clinical-trial/feed/ 0 Evidence-Based Review of BioBran/ MGN-3 Arabinoxylan Compound as a Complementary Therapy for Conventional Cancer Treatment https://biobran.org/evidence-based-review-of-biobran-mgn-3-arabinoxylan-compound-as-a-complementary-therapy-for-conventional-cancer-treatment/ Wed, 16 Aug 2017 19:15:00 +0000 https://biobran.org/?p=726 Abstract Introduction: Conventional cancer treatment, including surgery, chemotherapy, and radiotherapy, may not be sufficient to eradicate all malignant cells and prevent recurrence. Intensive treatment often leads to a depressed immune system, drug resistance, and toxicity, hampering the treatment outcomes. BioBran/MGN-3 Arabinoxylan is a standardized arabinoxylan concentrate which has been proposed as a plant-based immunomodulator that can restore the tumor-induced disturbance of the natural immune system, including natural killer cell activity to fight cancer, complementing conventional therapies. Objectives: To comprehensively review the available evidence on the effects and efficacies of MGN-3 as a complementary therapy for conventional cancer treatment. Methods: Systematic search of journal databases and gray literature for primary studies reporting the effects of MGN-3 on cancer and cancer treatment. Results: Thirty full-text articles and 2 conference abstracts were included in this review. MGN-3 has been shown to possess immunomodulating anticancer effects and can work synergistically with chemotherapeutic agents, in vitro. In murine models, MGN-3 has been shown to act against carcinogenic agents, and inhibit tumor growth, either by itself or in combination with other anticancer compounds. Fourteen successful MGN-3 treated clinical cases were found. Eleven clinical studies, including 5 nonrandomized, pre-post intervention studies and 6 randomized controlled trials (RCTs) were located. Reported effects include enhanced immunoprofile, reduced side effects, improved treatment outcomes; one RCT established significantly increased survival rates. There are no reports on adverse events on MGN-3. Most of the clinical trials are small studies with short duration. Conclusion: There is sufficient evidence suggesting MGN-3 to be an effective immunomodulator that can complement conventional cancer treatment. However, more well-designed RCTs on MGN-3 are needed to strengthen the evidence base.

]]>